Physician profile
Daniel Mansour
NPI 1841425592
$13,402.84
in general payments reported to CMS, 2019-2025
11 companies · $9,144 in 2025
The $9,144 reported for 2025 was more than what 89% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,832 · 2020: $23.15 · 2021: $566 · 2022: $174 · 2023: $199 · 2024: $1,465 · 2025: $9,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Travel and Lodging: $3,635 · Food and Beverage: $1,164 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Travel and Lodging | $3,634.58 |
| Food and Beverage | $1,164.35 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,521.60 | 2019-2025 | |
| Davol INC. | $255.48 | 2023-2025 | Channel Drain, Phasix Mesh |
| Galvanize Therapeutics, INC | $176.49 | 2024 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $109.47 | 2022 | |
| Atricure, INC. | $104.29 | 2023-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Medtronic, INC. | $85.04 | 2022-2024 | Signia |
| Becton, Dickinson and Company | $57.14 | 2024 | Channel Drain |
| Astrazeneca Pharmaceuticals LP | $31.54 | 2022-2023 | Imfinzi |
| Covidien LP | $23.15 | 2020 | |
| Olympus America INC. | $23.04 | 2024 | Visera Elite II Video System Center |
| Pacira Pharmaceuticals Incorporated | $15.60 | 2023 | Exparel, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.